Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen

Abstract The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology. Dry eye disease manifests as tear-layer instability and inflammation caused by osmotic hypersensitization in tear fluids; however, to our knowledge, no agen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miyuki Kubota, Motoko Kawashima, Sachiko Inoue, Toshihiro Imada, Shigeru Nakamura, Shunsuke Kubota, Mitsuhiro Watanabe, Ryo Takemura, Kazuo Tsubota
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ad49727e1bbb448384830f2eb0775214
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ad49727e1bbb448384830f2eb0775214
record_format	dspace
spelling	oai:doaj.org-article:ad49727e1bbb448384830f2eb07752142021-12-02T13:17:48ZRandomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen10.1038/s41598-021-85895-y2045-2322https://doaj.org/article/ad49727e1bbb448384830f2eb07752142021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85895-yhttps://doaj.org/toc/2045-2322Abstract The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology. Dry eye disease manifests as tear-layer instability and inflammation caused by osmotic hypersensitization in tear fluids; however, to our knowledge, no agent that treats both pathologies simultaneously is available. Molecular hydrogen (H2) is known to be effective against various diseases; therefore, we aimed to elucidate the effects of H2 on tear dynamics and the treatment of dry eye disease. We revealed that administering a persistent H2-generating supplement increased the human exhaled H2 concentration (p < 0.01) and improved tear stability (p < 0.01) and dry eye symptoms (p < 0.05) significantly. Furthermore, H2 significantly increased tear secretion in healthy mice (p < 0.05) and significantly suppressed tear reduction in a murine dry eye model (p = 0.007). H2 significantly and safely improved tear stability and dry eye symptoms in a small exploratory group of 10 human subjects, a subset of whom reported dry eye symptoms prior to treatment. Furthermore, it increased tear secretion rapidly in normal mice. Therefore, H2 may be a safe and effective new treatment for dry eye disease and thus larger trials are warranted.Miyuki KubotaMotoko KawashimaSachiko InoueToshihiro ImadaShigeru NakamuraShunsuke KubotaMitsuhiro WatanabeRyo TakemuraKazuo TsubotaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Miyuki Kubota Motoko Kawashima Sachiko Inoue Toshihiro Imada Shigeru Nakamura Shunsuke Kubota Mitsuhiro Watanabe Ryo Takemura Kazuo Tsubota Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
description	Abstract The incidence of dry eye disease is increasing worldwide because of the aging population and increasing use of information technology. Dry eye disease manifests as tear-layer instability and inflammation caused by osmotic hypersensitization in tear fluids; however, to our knowledge, no agent that treats both pathologies simultaneously is available. Molecular hydrogen (H2) is known to be effective against various diseases; therefore, we aimed to elucidate the effects of H2 on tear dynamics and the treatment of dry eye disease. We revealed that administering a persistent H2-generating supplement increased the human exhaled H2 concentration (p < 0.01) and improved tear stability (p < 0.01) and dry eye symptoms (p < 0.05) significantly. Furthermore, H2 significantly increased tear secretion in healthy mice (p < 0.05) and significantly suppressed tear reduction in a murine dry eye model (p = 0.007). H2 significantly and safely improved tear stability and dry eye symptoms in a small exploratory group of 10 human subjects, a subset of whom reported dry eye symptoms prior to treatment. Furthermore, it increased tear secretion rapidly in normal mice. Therefore, H2 may be a safe and effective new treatment for dry eye disease and thus larger trials are warranted.
format	article
author	Miyuki Kubota Motoko Kawashima Sachiko Inoue Toshihiro Imada Shigeru Nakamura Shunsuke Kubota Mitsuhiro Watanabe Ryo Takemura Kazuo Tsubota
author_facet	Miyuki Kubota Motoko Kawashima Sachiko Inoue Toshihiro Imada Shigeru Nakamura Shunsuke Kubota Mitsuhiro Watanabe Ryo Takemura Kazuo Tsubota
author_sort	Miyuki Kubota
title	Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
title_short	Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
title_full	Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
title_fullStr	Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
title_full_unstemmed	Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
title_sort	randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ad49727e1bbb448384830f2eb0775214
work_keys_str_mv	AT miyukikubota randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT motokokawashima randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT sachikoinoue randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT toshihiroimada randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT shigerunakamura randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT shunsukekubota randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT mitsuhirowatanabe randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT ryotakemura randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen AT kazuotsubota randomizedcrossoverclinicalefficacytrialinhumansandmiceontearsecretionpromotionandlacrimalglandprotectionbymolecularhydrogen
_version_	1718393350861619200

Randomized, crossover clinical efficacy trial in humans and mice on tear secretion promotion and lacrimal gland protection by molecular hydrogen

Ejemplares similares